ClariVest Asset Management LLC boosted its holdings in shares of BioTelemetry Inc (NASDAQ:BEAT) by 176.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 56,936 shares of the medical research company’s stock after buying an additional 36,336 shares during the quarter. ClariVest Asset Management LLC owned approximately 0.17% of BioTelemetry worth $3,400,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also made changes to their positions in BEAT. BlackRock Inc. grew its position in BioTelemetry by 7.8% during the third quarter. BlackRock Inc. now owns 4,957,817 shares of the medical research company’s stock valued at $319,531,000 after buying an additional 360,529 shares during the period. Loomis Sayles & Co. L P bought a new position in shares of BioTelemetry in the third quarter worth approximately $23,211,000. Fuller & Thaler Asset Management Inc. bought a new position in shares of BioTelemetry in the third quarter worth approximately $9,947,000. Credit Suisse AG boosted its position in shares of BioTelemetry by 18.2% in the third quarter. Credit Suisse AG now owns 826,222 shares of the medical research company’s stock worth $53,250,000 after purchasing an additional 127,195 shares during the period. Finally, Point72 Asset Management L.P. boosted its position in shares of BioTelemetry by 332.4% in the third quarter. Point72 Asset Management L.P. now owns 92,100 shares of the medical research company’s stock worth $5,936,000 after purchasing an additional 70,800 shares during the period. Institutional investors own 90.54% of the company’s stock.
BEAT opened at $76.30 on Thursday. The company has a market capitalization of $2.50 billion, a price-to-earnings ratio of 78.66, a PEG ratio of 4.16 and a beta of 1.75. BioTelemetry Inc has a 1-year low of $29.85 and a 1-year high of $80.92. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.68 and a quick ratio of 2.50.
A number of equities analysts have weighed in on the stock. ValuEngine upgraded shares of BioTelemetry from a “buy” rating to a “strong-buy” rating in a research report on Monday, February 4th. Zacks Investment Research lowered shares of BioTelemetry from a “buy” rating to a “hold” rating in a research report on Monday, February 4th. Sidoti set a $95.00 price target on shares of BioTelemetry and gave the stock a “buy” rating in a research report on Tuesday, February 5th. BidaskClub upgraded shares of BioTelemetry from a “buy” rating to a “strong-buy” rating in a research report on Friday, January 11th. Finally, Raymond James dropped their price target on shares of BioTelemetry from $66.00 to $64.00 and set an “outperform” rating for the company in a research report on Wednesday, October 31st. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $70.57.
BioTelemetry, Inc, a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology.
Featured Story: Preferred Stock
Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.